Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Phase 1
Completed
Conditions
Lymphoma
Interventions
Drug: vorinostat
First Posted Date
2005-08-05
Last Posted Date
2015-09-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
10
Registration Number
NCT00127140

A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Phase 3
Completed
Conditions
Healthy
Pneumococcal Infections
First Posted Date
2005-08-05
Last Posted Date
2015-01-29
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
130
Registration Number
NCT00127153

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

First Posted Date
2005-08-04
Last Posted Date
2017-04-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00126451

A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)

First Posted Date
2005-07-28
Last Posted Date
2016-08-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
149
Registration Number
NCT00124735

A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia

Phase 3
Completed
Conditions
Anesthesia
Interventions
Drug: Rocuronium bromide (Zemuron)
First Posted Date
2005-07-28
Last Posted Date
2015-06-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
207
Registration Number
NCT00124722

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Phase 2
Completed
Conditions
Endometrial Cancer
Interventions
Drug: ridaforolimus
First Posted Date
2005-07-22
Last Posted Date
2015-02-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
45
Registration Number
NCT00122343

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Phase 1
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-07-19
Last Posted Date
2010-06-10
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT00120835

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

Phase 2
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-07-19
Last Posted Date
2010-06-10
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT00120861

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

Phase 2
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-07-12
Last Posted Date
2009-03-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
175
Registration Number
NCT00118768

MARS - Monitored Atherosclerosis Regression Study

Phase 2
Completed
Conditions
Atherosclerosis
Coronary Artery Disease
First Posted Date
2005-07-01
Last Posted Date
2009-12-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
270
Registration Number
NCT00116870
Locations
🇺🇸

Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy